Status:
COMPLETED
Intranasal Oxytocin in Antiosocial Personality Disorder and Psychopathy
Lead Sponsor:
King's College London
Collaborating Sponsors:
Father Flanagan's Boys' Home
Conditions:
Antisocial Personality Disorder
Eligibility:
MALE
18-60 years
Phase:
NA
Brief Summary
A pharmacoimaging study of oxytcoin in antisocial personality disorder and psychopathy
Detailed Description
Using a double-blinded, placebo controlled design, we explored similarities and differences in i) an important component of empathic processing (neural response to facial emotional expressions) and ii...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male
- Aged 18-60
- IQ greater than 70 as defined by the Wechsler Abbreviated Scale of Intelligence (WASI-II).
- Violent offenders:
- Offenders with convictions for violent crimes (murder, rape, attempted murder, grievous and actual bodily harm) who met DSM-5 criteria for antisocial personality disorder (Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5 PD) Psychopathy or non-psychopathy subgroup based on Psychopathy Checklist- Revised (PCL-R; (Hare, 2003))- score of 25 as the threshold for psychopathy in this English population.
- Healthy non-offenders:
- Non-offenders with no personality disorder
- Exclusion criteria:
- history of major mental disorders (bipolar 1, bipolar 2, major depression or psychotic disorders)
- self-reported neurological disorders
- head injury resulting in loss of consciousness for 1 hour or longer
- severe visual or hearing impairments
- contraindications to MRI
Exclusion
Key Trial Info
Start Date :
May 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT05383300
Start Date
May 1 2017
End Date
December 1 2021
Last Update
May 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Insititue of Psychiarty, Psychology and Neuroscience
London, Nottinghamshire, United Kingdom, SE58AF